Evidence map›Paper›PMID 19812908›Full record

ReviewDer Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen2009

[Principles of neoadjuvant therapy].

F Lordick

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

F LordickMedizinische Klinik III, Innere Medizin, Hämatologie und Onkologie, Klinikum Braunschweig, Celler Strasse 38, 38114, Braunschweig, Deutschland. medklinik3@klinikum-braunschweig.de
Klinikum Braunschweig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant therapy is now an integral part in the treatment of locally advanced cancer of the esophagus and stomach. The mechanisms of action comprise downsizing of the primary tumor, improvement of the T and N categories and the earliest possible eradication of micrometastases. Several controlled clinical studies could show that these principles can indeed augment the rate of curative (R0) resections and can reduce the likelihood of systemic recurrences. As a consequence overall survival is improved by neoadjuvant therapy. This article summarizes how the basic principles of neoadjuvant therapy translate into clinical practice and gives a review of current developmental perspectives in this field.

Indexed as

Neoadjuvant TherapyAdenocarcinomaCarcinoma, Squamous CellClinical Trials as TopicCombined Modality TherapyDisease-Free SurvivalEsophageal NeoplasmsEsophagectomyGastrectomyHumansLymphatic MetastasisNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPrognosis

Identifiers

PMID19812908
OpenAlexW2166421874

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.